Navigation Links
Extensive Scientific Data Supports the Clinical Validity of Pharmacogenomic Testing for Predicting Patient Response to Psychiatric Medications
Date:10/28/2013

MASON, Ohio, Oct. 28, 2013 /PRNewswire/ -- Assurex Health, a leading personalized medicine company, announced today that the International Review of Psychiatry published an extensive review that validates the clinical use of pharmacogenomic testing to help predict patient response to psychiatric medications and improve treatment outcomes. The paper provides substantial evidence that psychiatric pharmacogenomic testing has proven clinical value in predicting how individual patients will tolerate and respond to specific psychiatric medications. These findings refute results of a previous assessment of pharmacogenomic testing conducted in 2007 by the Evaluation of Genomic Applications in Practice and Prevention initiative (EGAPP) which concluded that there was insufficient evidence to determine the value of pharmacogenomic testing for adults beginning treatment with SSRI antidepressants.

(Logo: http://photos.prnewswire.com/prnh/20130910/CL75944LOGO )

The current article titled "Clinical Validity of Cytochrome P450 Metabolism and Serotonin Gene Variants in Psychiatric Pharmacotherapy"* reviewed published data collected since 2007 examining how DNA sequence variations between individuals can affect their metabolism and response to medications.  The preponderance of evidence from these studies supports the validity of analyzing patients' genetic profile to predict the metabolism, safety, and therapeutic efficacy of psychotropic medications commonly used for the treatment of depression, schizophrenia, and bipolar disorder.    

"A review of 294 scientific studies published since the EGAPP report clearly demonstrates the clinical validity of multiple genes in predicting patient responses to antidepressant medications.  This assessment is further supported by multiple clinical trials demonstrating that understanding variations in these same genes leads to better treatment decisions and better patient outcomes," said C. Anthony Altar, Ph.D., Chief Science Officer of Assurex Health and lead author.   

"The review of these clinical and scientific data clearly reinforces the benefits of pharmacogenomic testing in aiding medication selection and augmenting patient responses to antidepressant and antipsychotic medications. Use of pharmacogenomic testing leads to earlier identification of optimal treatment protocols for individual patients," said Assurex Health CEO James S. Burns.  "The question is no longer whether pharmacogenomic testing is ready for routine clinical use; rather, how to make it available earlier in the course of patient treatment to improve patient outcomes."   
  
About the Publication   

The authors conducted a systematic literature review to assess whether pharmacokinetic (PK) or pharmacodynamic (PD) responses to 26 commonly prescribed antidepressant and antipsychotic medications, including efficacy or side effects, are associated with nucleotide polymorphisms in eight commonly studied genes in psychiatric pharmacotherapy.  Of the 294 publications reviewed, a majority showed significant associations between polymorphisms and patient response to psychotropic medications.  In many cases, a lack of association was traced to inappropriate comparisons between a medication and the gene being evaluated.  The findings showed that combinatorial pharmacogenomic tests can help predict genetically appropriate medication choices and improve patient outcomes.      

*Authors of the article are: C. Anthony Altar, Ph.D., John Hornberger, M.D., M.S., Ashwini Shewade, M.S., M.Sc., Victor Cruz, B.S., Jill Garrison, M.S. and David Mrazek, M.D., FRC-Psych.  The review has been dedicated to the memory of David A. Mrazek, a pioneer in the theory and clinical application of psychiatric pharmacogenomics.   

About Assurex Health  

Assurex Health is a personalized medicine company that specializes in pharmacogenomics and is dedicated to helping physicians determine the right medication for individual patients suffering from neuropsychiatric and other disorders. The company was founded to commercialize industry-leading personalized medicine technology for neuropsychiatric disorders. Assurex Health has licensed technology from Mayo Clinic and Cincinnati Children's Hospital Medical Center. Mayo Clinic has a financial interest in the technology referenced in this news release.   

For more information about Assurex Health, please visit www.assurexhealth.com.   

About GeneSight   

GeneSight is a laboratory-developed pharmacogenomic test that uses cutting edge technology to measure and analyze clinically important genomic variants in the treatment of psychiatric disorders. The results of the GeneSight report can help a clinician understand the way a patient's unique genomic makeup may affect certain psychiatric drugs. The analysis is based on pharmacogenomics, the study of genomic factors that influence an individual's response to drug treatments, manufacturers' FDA approved drug labels, peer reviewed scientific and clinical publications, and proven drug pharmacology.  Quick turnaround time, combined with a customized report of the patient's genomic makeup, clinical experience, and other factors can provide information to help a physician make personalized drug treatment choices for each patient.  

Registered trademarks are the property of their respective owners.   


'/>"/>
SOURCE Assurex Health
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Frost & Sullivan Recognizes ASCEND HiT for Providing Extensive Value Enhancement to Industry Partners and Providers through its Best-of-Breed Products
2. Abilities Expo -- The Nations Leading Expo for People with Disabilities -- to Feature Push Girls star, Auti Angel, along with an extensive Line Up of New Products, Services and Technology at Reliant Center, August 2-4
3. Leading Home Medical Supplies Retailer Med Supply Shop Spotlights Its Extensive Inventory of Power Wheelchairs
4. For Treatment of Extensive-Disease Small-Cell Lung Cancer (ED-SCLC), No Emerging Therapy is Likely to Replace Etoposide/Carboplatin as the Standard of Care Before 2022
5. Home Medical Supply Store MedSupplyShop.com Showcases Its Extensive Range of Medical Products
6. ALCOR Scientific Inc. Welcomes New COO
7. Boston Scientific Receives Prestigious 2013 Prix Galien Award For Best Medical Technology
8. Osteo Science Foundation to Support Scientific and Clinical Research in Oral and Maxillofacial Surgery
9. Anthera Pharmaceuticals Announces Emerging Data from Phase 2 Open-Label Extension Study to be Presented at the ACR/ARHP 2013 Annual Scientific Meeting
10. Heart Failure Society of America 17th Annual Scientific Meeting To Focus On New Developments In Heart Failure Cause, Care And Treatment
11. New York Genome Center Launches Groundbreaking Consortium to Accelerate Scientific and Clinical Discoveries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... 2016 Story Highlights: ... within the health care industry is causing providers to ... , Deloitte offers a suite of solutions for health ... efficient cost optimization: labor resource analysis, revenue cycle optimization ... better outcomes and better economics ...
(Date:6/24/2016)... , June 24, 2016   Bay ... Rehabilitation Network,s Dean Center for Tick Borne ... Medicine and Rehabilitation, MIT Hacking Medicine, University of ... Innovation, today announced the five finalists of ... Lyme disease.  More than 100 scientists, clinicians, researchers, ...
(Date:6/24/2016)... 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... markets and sells medical devices and wearable sleep respiratory ... strategic cooperation agreement with Hongyuan Supply Chain Management Co., ... June 20, 2016, to develop Dehaier,s new Internet medical ... Dehaier will leverage Hongyuan Supply Chain,s sales platform to ...
Breaking Medicine Technology:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... On Friday, ... presented a Bronze Wellness at Work award to iHire in recognition of their exemplary ... part of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
Breaking Medicine News(10 mins):